179 related articles for article (PubMed ID: 26993766)
1. Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.
Destouches D; Sader M; Terry S; Marchand C; Maillé P; Soyeux P; Carpentier G; Semprez F; Céraline J; Allory Y; Courty J; De La Taille A; Vacherot F
Oncotarget; 2016 Oct; 7(43):69397-69411. PubMed ID: 26993766
[TBL] [Abstract][Full Text] [Related]
2. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
3. N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.
De Cola A; Franceschini M; Di Matteo A; Colotti G; Celani R; Clemente E; Ippoliti R; Cimini AM; Dhez AC; Vallée B; Raineri F; Cascone I; Destouches D; De Laurenzi V; Courty J; Federici L
Cancer Lett; 2018 Jan; 412():272-282. PubMed ID: 29111347
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor (AR) degradation enhancer ASC-J9
Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
[TBL] [Abstract][Full Text] [Related]
5. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
6. New Therapeutic Target for Prostate Cancer.
Cancer Discov; 2016 Jun; 6(6):OF6. PubMed ID: 27091858
[TBL] [Abstract][Full Text] [Related]
7. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.
Wu M; Kim SH; Datta I; Levin A; Dyson G; Li J; Kaypee S; Swamy MM; Gupta N; Kwon HJ; Menon M; Kundu TK; Reddy GP
Oncotarget; 2015 Mar; 6(8):6136-50. PubMed ID: 25704883
[TBL] [Abstract][Full Text] [Related]
8. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
9. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
10. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.
Wadosky KM; Koochekpour S
Int J Biol Sci; 2016; 12(4):409-26. PubMed ID: 27019626
[TBL] [Abstract][Full Text] [Related]
13. Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
Neschadim A; Pritzker LB; Pritzker KP; Branch DR; Summerlee AJ; Trachtenberg J; Silvertown JD
Endocr Relat Cancer; 2014 Jun; 21(3):459-71. PubMed ID: 24812057
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals.
Cui Y; Sun Y; Hu S; Luo J; Li L; Li X; Yeh S; Jin J; Chang C
Oncogene; 2016 Nov; 35(47):6065-6076. PubMed ID: 27375022
[TBL] [Abstract][Full Text] [Related]
15. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
[TBL] [Abstract][Full Text] [Related]
16. Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model.
Benedetti E; Antonosante A; d'Angelo M; Cristiano L; Galzio R; Destouches D; Florio TM; Dhez AC; Astarita C; Cinque B; Fidoamore A; Rosati F; Cifone MG; Ippoliti R; Giordano A; Courty J; Cimini A
Oncotarget; 2015 Dec; 6(39):42091-104. PubMed ID: 26540346
[TBL] [Abstract][Full Text] [Related]
17. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
19. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
20. Regulation of androgen receptor expression by Z-isochaihulactone mediated by the JNK signaling pathway and might be related to cytotoxicity in prostate cancer.
Liu PY; Lin SZ; Sheu JJ; Lin CT; Lin PC; Chou YW; Huang MH; Chiou TW; Harn HJ
Prostate; 2013 Apr; 73(5):531-41. PubMed ID: 23038474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
